Literature DB >> 16879999

Selective delivery of rifampicin incorporated into poly(DL-lactic-co-glycolic) acid microspheres after phagocytotic uptake by alveolar macrophages, and the killing effect against intracellular Mycobacterium bovis Calmette-Guérin.

Aya Yoshida1, Makoto Matumoto, Hiroyuki Hshizume, Yoshiro Oba, Tatuo Tomishige, Hiroyuki Inagawa, Chie Kohchi, Mami Hino, Fuminori Ito, Keishiro Tomoda, Takehisa Nakajima, Kimiko Makino, Hiroshi Terada, Hitoshi Hori, Gen-Ichiro Soma.   

Abstract

Macrophages and their phagocytotic abilities play a dominant role for defense against infected organisms. However, Mycobacterium tuberculosis can survive in the phagosomes of macrophages. In this study, the effective delivery of a drug and the killing effect of tubercle bacilli within macrophages were investigated utilizing the phagocytotic uptake of rifampicin (RFP) that had been incorporated into poly(DL-lactic-co-glycolic) acid (PLGA) microspheres. The microspheres were composed of PLGA that had a monomer ratio (lactic acid/glycolic acid) of either 50/50 or 75/25. They had molecular weights from 5000 to 20,000, and diameters of 1.5, 3.5, 6.2 and 8.9 microm. The most significant factor for phagocytotic activity of macrophages was the diameter of the microspheres. By contrast, molecular weight and monomer ratio of PLGA did not influence phagocytosis. The amount of RFP delivered into cells was also investigated. RFP-PLGA microspheres composed of PLGA with a molecular weight of 20,000 and monomer ratio of 75/25 showed the highest amount of delivery (4 microg/1 x 10(6) cells). Fourteen days after infection, the survival rate of treated intracellular bacilli was 1% when compared with untreated cells. There was almost no killing effect of free RFP (4 or 15 microg/ml) on intracellular bacilli. In vivo efficacy of RFP-PLGA was also examined in rats infected with M. tuberculosis Kurono. Intratracheal administration of RFP-PLGA microspheres was shown to be superior to free RFP for killing of intracellular bacilli and preventing granuloma formation in some lobes. These results suggest that phagocytotic activity could be part of a new drug delivery system that selectively targeted macrophages.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16879999     DOI: 10.1016/j.micinf.2006.06.004

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  9 in total

1.  Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice.

Authors:  Rahul Kumar Verma; Jatinder Kaur; Kaushlendra Kumar; Awadh Bihari Yadav; Amit Misra
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

Review 2.  Inhaled drug delivery for tuberculosis therapy.

Authors:  Pavan Muttil; Chenchen Wang; Anthony J Hickey
Journal:  Pharm Res       Date:  2009-11       Impact factor: 4.200

3.  Control of drug loading efficiency and drug release behavior in preparation of hydrophilic-drug-containing monodisperse PLGA microspheres.

Authors:  Fuminori Ito; Hiroyuki Fujimori; Hiroyuki Honnami; Hiroyoshi Kawakami; Kiyoshi Kanamura; Kimiko Makino
Journal:  J Mater Sci Mater Med       Date:  2010-02-03       Impact factor: 3.896

4.  Application of a four-fluid nozzle spray drier to prepare inhalable rifampicin-containing mannitol microparticles.

Authors:  Takuto Mizoe; Tetsuya Ozeki; Hiroaki Okada
Journal:  AAPS PharmSciTech       Date:  2008-06-18       Impact factor: 3.246

5.  Stimulation of phagocytic activity of alveolar macrophages toward artificial microspheres by infection with mycobacteria.

Authors:  Keiji Hirota; Keishiro Tomoda; Hiroyuki Inagawa; Chie Kohchi; Gen-Ichiro Soma; Kimiko Makino; Hiroshi Terada
Journal:  Pharm Res       Date:  2008-06       Impact factor: 4.200

Review 6.  Nanobead-based interventions for the treatment and prevention of tuberculosis.

Authors:  Gareth Griffiths; Bo Nyström; Suraj B Sable; Gopal K Khuller
Journal:  Nat Rev Microbiol       Date:  2010-10-12       Impact factor: 60.633

7.  Single-dose Ag85B-ESAT6-loaded poly(lactic-co-glycolic acid) nanoparticles confer protective immunity against tuberculosis.

Authors:  Anshu Malik; Manish Gupta; Rajesh Mani; Rakesh Bhatnagar
Journal:  Int J Nanomedicine       Date:  2019-05-01

8.  Glucosamine/L-lactide copolymers as potential carriers for the development of a sustained rifampicin release system using Mycobacterium smegmatis as a tuberculosis model.

Authors:  Jorge Ragusa; Daniela Gonzalez; Sumin Li; Sandra Noriega; Maciej Skotak; Gustavo Larsen
Journal:  Heliyon       Date:  2019-04-28

9.  Systems Pharmacology Approach Toward the Design of Inhaled Formulations of Rifampicin and Isoniazid for Treatment of Tuberculosis.

Authors:  N A Cilfone; E Pienaar; G M Thurber; D E Kirschner; J J Linderman
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-03-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.